Registry for adults with severe asthma receiving biologic treatments in Taiwan
Taiwan Severe Asthma Biologic Registry
This study is tracking adults with severe asthma in Taiwan who are using biologic treatments to see how well they work and what factors might help choose the best options.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Taichung Veterans General Hospital Academic / other |
| Drugs / interventions | omalizumab, mepolizumab, benralizumab, dupilzumab, Tezepelumab |
| Locations | 1 site (Taichung) |
| Trial ID | NCT06456450 on ClinicalTrials.gov |
What this trial studies
This observational study aims to register adult patients with severe asthma who are receiving biologic treatments in Taiwan. It will evaluate the real-world effectiveness of these treatments, the impact of initiating or switching biologics, and identify potential factors that predict the best treatment options. The study will also assess risk factors associated with poor asthma control and compare the clinical remission rates among different biologics. Participants will include those treated with omalizumab, mepolizumab, benralizumab, dupilumab, or Tezep.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old with severe asthma who have started biologic treatment after January 1, 2020.
Not a fit: Patients with a history of biologic treatment prior to January 1, 2020, or those with significant comorbid pulmonary diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into the most effective biologic treatments for severe asthma, leading to improved patient outcomes.
How similar studies have performed: Other studies have shown success in evaluating the effectiveness of biologics for severe asthma, making this approach both relevant and supported by prior findings.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Provision of informed consent prior to any study specific procedures. * Patient should be reviewed as well as confirmed by the National Health Insurance Administration (NHIA) or by the study board member as a Severe Asthma case. * Female and male aged over 18 years old. * Patients who are treated either with omalizumab, mepolizumab, or benralizumab after January 1, 2020. Exclusion Criteria: * Lack of informed consent for participation. * History of Biologic usage before January 1, 2020, should be ruled out. * The washout period should be at least 12 months. In other words, the enrolled patients should have no experience in receiving a biological treatment or in participating relative clinical trial before his/her biologic initiation. * Comorbid pulmonary diseases (e.g.: Chronic Obstructive Pulmonary Disease, Bronchiectasis, Pulmonary Fibrosis, etc.) or risk factors (e.g.: smoking or environmental exposure, etc..) that could be associated with pulmonary or systemic diseases, other than Asthma.
Where this trial is running
Taichung
- Taichung Veterans General Hospital — Taichung, Taiwan (Recruiting)
Study contacts
- Study coordinator: Pin-Kuei Fu, MD.,PhD.
- Email: yetquen@gmail.com
- Phone: 886-4-23592525
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.